OVERVIEW
At YNIOS PHARMA, we are driven by a singular mission: to transform the landscape of critical care. Our compound TA64 is expected to increase patient’s survival rate, protect from organ failure and complications, and reduce ICU stay length. Our company was born out of a deep commitment to improving outcomes for patients in life-threatening conditions where time and precision are crucial.
OUR VISION
Our vision is to be at the forefront of critical care innovation, providing healthcare professionals with the tools they need to save lives and improve recovery outcomes. We are committed to advancing medical science and delivering solutions that not only treat but also prevent the severe complications associated with critical care indications.
OUR STORY
YNIOS PHARMA began with a clear purpose—harnessing cutting-edge research to solve one of the most challenging problems in intensive care medicine. The founders recognized a critical gap in the treatment of conditions with tissue damage, organ failure, and high mortality rates. With a shared passion for scientific innovation and patient care, they embarked on a journey to develop a novel therapeutic approach that could redefine critical care practices.
OUR TEAM
YNIOS PHARMA is led by co-founders Philippe Van Wesepoel and Jean François Plucker, who bring a unique combination of skills and experience to the company.
Philippe is a forward-looking R&D professional with deep expertise in cellular physiology and a strong translational medicine mindset. With a solid background in the pharmaceutical industry, he focuses on connecting disease mechanisms and translating complex processes of cellular sensing, injury, and repair into actionable therapeutic strategies.
His work bridges cellular resilience and innate immune repair, aiming to develop innovative therapies that restore balance and strengthen the body’s natural defense systems. At the intersection of biology and artificial intelligence, he applies Prompt AI and generative AI to accelerate R&D, optimize data-driven decision-making, and uncover new biological insights that drive the creation of precise and effective therapies.
As a partner of the IP firm Kirkpatrick (www.kirkpatrick.eu), Jean François combines a strong foundation in intellectual property strategy with hands-on business and innovation management experience. He has worked in Europe and in the United-States, helping companies, research centers, and investors build value from technology through smart IP protection, licensing, and commercialization strategies. Jean François is recognized for his ability to connect scientific excellence with business opportunity.
Together with their research team, they bring a wealth of knowledge, experience, and a shared vision for transforming critical care treatment. Their commitment to understanding the intricate mechanisms of cellular injury and repair drives the development of innovative solutions that address the complex challenges faced in critical care settings.
OUR COMMITMENT
We are committed to rigorous scientific research, ethical practices, and the relentless pursuit of innovation. As we advance through our clinical development phases, we remain focused on our ultimate goal: to bring TA64 to the bedside, where it can make a tangible difference in the lives of patients facing critical health challenges.
At YNIOS PHARMA, we believe that by advancing science, we advance care. We invite you to join us on this journey towards a new era in critical care medicine.